A case of synchronous double cancer responding to UFT--dermoid cyst with secondary malignant transformation and uterine endometrial adenocarcinoma

• Published in: Gan to kagaku ryoho Vol. 32; no. 1; p. 103
• Main Authors: Takami, Masashi, Maruyama, Aya, Fukai, Hiroshi, Matsumoto, Hiroshi, Togo, Yoshichika, Takimoto, Toshirou, Sakamoto, Hideki, Yamamoto, Tatsuo
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.01.2005
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Adenocarcinoma - surgery; Adult; Antineoplastic Agents - therapeutic use; Carcinoma, Adenosquamous - pathology; Combined Modality Therapy; Dermoid Cyst - drug therapy; Dermoid Cyst - pathology; Dermoid Cyst - surgery; Drug Combinations; Endometrial Neoplasms - drug therapy; Endometrial Neoplasms - pathology; Endometrial Neoplasms - surgery; Female; Humans; Hysterotomy; Neoplasms, Multiple Primary - pathology; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Ovarian Neoplasms - surgery; Ovariectomy; Quality of Life; Salpingostomy; Tegafur - therapeutic use; Uracil - therapeutic use
• ISSN: 0385-0684

We report here a case of synchronous dermoid cyst with secondary malignant tumor and uterine endometrial adenocarcinoma that responded to UFT. A 35-year-old female complained of abdominal fullness and visited our hospital. She had an abdominal mass which was newborn-head size. We performed right salpingo-oophorectomy and partial omentectomy. The pathological findings were dermoid cyst with secondary malignant transformation. After the operation she had underwent cyclic chemotherapy with CDDP, CPA, THP and 5-FU. After three cycles of chemotherapy, a uterine recurrence was suspected from her uterine endocervical smear test. Then we performed a second operation, but radical surgery was impossible due to the presence of multiple metastases to pelvic lymph nodes. The pathological findings were primary uterine endometrial adenocarcinoma, not metastasis from dermoid cyst with secondary malignant tumor. After the second operation, she was treated with oral UFT (400 mg/day), as she refused chemotherapy and radiotherapy. Two months after the start of UFT, the tumor markers were reduced remarkably, and the patient maintained good QOL throughout the treatment without serious adverse events. We conclude that UFT might be benefical in the treatment of advanced gynecologic cancer.